[Form 4/A] Sensus Healthcare, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Sensus Healthcare, Inc. insider Michael Sardano, who serves as President, General Counsel, and a director of the company, reported open-market purchases of SRTS common stock. On 11/11/2025, he bought 1,000 shares of common stock at a price of $4.26 per share, bringing his directly owned holdings to 117,839 shares.

On the same date, his spouse purchased 766 shares at $4.27 per share and 234 shares at $4.34 per share, for a total of 1,000 shares held in the spouse’s name. The filing notes that Sardano disclaims beneficial ownership of the shares held by his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sardano Michael

(Last) (First) (Middle)

851 BROKEN SOUND PARKWAY NW

STE. 215

(Street)

BOCA RATON FL 33487

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sensus Healthcare, Inc. [ SRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND GENERAL COUNSEL

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/13/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		P		1,000	A	$4.26	117,839	D
Common Stock	11/11/2025		P		766	A	$4.27	766	I	spouse(1)
Common Stock	11/11/2025		P		234	A	$4.34	1,000	I	spouse(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by Mr. Sardano's spouse, as to which he disclaims beneficial ownership.

	/s/ Michael Sardano	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sensus Healthcare (SRTS) report for Michael Sardano?

The filing reports that Michael Sardano, President, General Counsel, and director of Sensus Healthcare, Inc. (SRTS), purchased SRTS common stock in open-market transactions on 11/11/2025, and also reported purchases made by his spouse.

How many Sensus Healthcare (SRTS) shares did Michael Sardano buy and at what price?

On 11/11/2025, Michael Sardano bought 1,000 shares of SRTS common stock at a price of $4.26 per share, increasing his directly owned position.

What is Michael Sardano’s total direct ownership in Sensus Healthcare after the reported trades?

Following the reported transaction on 11/11/2025, Michael Sardano beneficially owns 117,839 shares of Sensus Healthcare common stock in direct ownership.

What Sensus Healthcare (SRTS) share purchases were made by Michael Sardano’s spouse?

On 11/11/2025, Sardano’s spouse purchased 766 shares of SRTS at $4.27 per share and 234 shares at $4.34 per share, for a total of 1,000 shares held by the spouse.

Does Michael Sardano claim beneficial ownership of his spouse’s Sensus Healthcare shares?

No. The filing explains that the shares held by Mr. Sardano’s spouse are reported, but he disclaims beneficial ownership of those shares.

What roles does Michael Sardano hold at Sensus Healthcare (SRTS)?

Michael Sardano is reported as both a director and an officer of Sensus Healthcare, serving as President and General Counsel.